Leire
Arbea Moreno
Consultora Médica
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (25)
2024
-
Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines
Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347
2023
-
"What medical students with better academic results do: a cross-sectional analysis"
BMC medical education, Vol. 23, Núm. 1, pp. 19
2020
2019
-
Long-term results of Perioperative High Dose Rate Brachytherapy (PHDRB) and external beam radiation in adult patients with soft tissue sarcomas of the extremities and the superficial trunk: Final results of a prospective controlled study
Radiotherapy and Oncology, Vol. 135, pp. 91-99
-
Student’s inventory of professionalism (Sip): A tool to assess attitudes towards professional development based on palliative care undergraduate education
International Journal of Environmental Research and Public Health, Vol. 16, Núm. 24
-
Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse
Cancers, Vol. 11, Núm. 5
2017
-
Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 969-975
2016
-
Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes
Brachytherapy, Vol. 15, Núm. 2, pp. 127-135
-
Valoración de tutores clínicos y estudiantes de medicina respecto a las rotaciones en centros de atención primaria y hospitales
Atencion Primaria
2015
-
Long-term oncologic results in cancer of the rectum treated by preoperative chemoradiotherapy and surgery: An analysis of 500 cases
Revista Espanola de Enfermedades Digestivas, Vol. 107, Núm. 6, pp. 340-346
-
Pneumomediastinum as a complication of SABR for lung metastases
Radiation Oncology, Vol. 10, Núm. 1
-
The Role of Intensity-Modulated Radiotherapy to Optimize Outcomes in Locally Advanced Rectal Cancer
Current Colorectal Cancer Reports, Vol. 11, Núm. 6, pp. 345-351
-
Time to loading and locoregional control in perioperative high-dose-rate brachytherapy: The tumor bed effect revisited
Brachytherapy, Vol. 14, Núm. 4, pp. 565-570
2013
-
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy
Diseases of the Colon and Rectum, Vol. 56, Núm. 4, pp. 416-421
2012
-
External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: Preliminary data on clinical outcome
International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 3
-
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial
International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593
-
Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review
Radiation Oncology, Vol. 7, Núm. 1
2011
-
Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB)
International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 4
2010
-
A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer
International Journal of Gynecological Cancer, Vol. 20, Núm. 1, pp. 133-140
-
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
Cancer Chemotherapy and Pharmacology, Vol. 65, Núm. 3, pp. 457-465